Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment

被引：15
|
作者：
Yang, Fei-Fei [1 ,2 ,3 ,4 ]
Hu, Ting [1 ,2 ,3 ,4 ]
Liu, Jian-Quan [1 ,2 ,3 ,4 ]
Yu, Xiao-Qian [1 ,2 ,3 ,4 ]
Ma, Li-Ying [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Minist Educ China, Key Lab Adv Pharmaceut Technol, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Inst Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[4] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[5] China Meheco Topfond Pharmaceut Co, Key Lab Cardio Cerebrovasc Drug, Zhumadian 463000, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 245卷
基金：
中国博士后科学基金;
关键词：
Hematologic cancer; HDACs; Immunotherapy; NKG2D LIGAND EXPRESSION; B-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; NON-HODGKIN-LYMPHOMA; REGULATORY T-CELLS; MULTIPLE-MYELOMA; ANTITUMOR IMMUNITY; VALPROIC ACID; TUMOR-CELLS; IN-VIVO;
D O I：
10.1016/j.ejmech.2022.114920
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bone marrow transplantation is regarded as the most effective immunotherapy for hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of histone deacetylases (HDACs) is closely related to the occurrence and development of hematological cancer. Recent studies suggested that HDACs might play a critical role in initiating anti-cancer immune response or enhancing anti-cancer immunotherapy. Besides, combining HDAC inhibition and immunotherapy could prevent immunotherapy resistance in some degree and reach an extended treatment window. This review summarized the relationship between HDACs and immune and described the current understanding of HDACs in immunotherapy for hematologic cancer.
引用
收藏
页数：13
相关论文
共 50 条
  • [41] Histone deacetylases and cancer
    M A Glozak
    E Seto
    Oncogene, 2007, 26 : 5420 - 5432
  • [42] Histone deacetylases and cancer
    Glozak, M. A.
    Seto, E.
    ONCOGENE, 2007, 26 (37) : 5420 - 5432
  • [43] Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
    Rodrigues, Daniel A.
    Pinheiro, Pedro de S. M.
    Sagrillo, Fernanda S.
    Bolognesi, Maria L.
    Fraga, Carlos A. M.
    MEDICINAL RESEARCH REVIEWS, 2020, 40 (06) : 2177 - 2211
  • [44] Promising immunotherapeutic targets for treating candidiasis
    Feng, Zhe
    Lu, Hui
    Jiang, Yuanying
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [45] Targeting histone deacetylases: development of vorinostat for the treatment of cancer
    Richon, Victoria M.
    EPIGENOMICS, 2010, 2 (03) : 457 - 465
  • [46] Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment
    Beumer, Jan H.
    Tawbi, Hussein
    CURRENT CLINICAL PHARMACOLOGY, 2010, 5 (03): : 196 - 208
  • [47] Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
    Zhang, Qing
    Wang, Shaobin
    Chen, Junhui
    Yu, Zhendong
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (03): : 424 - 442
  • [48] MODULATION OF FIBROSIS AND ANGIOGENESIS IN SYSTEMIC SCLEROSIS (SSC) BY SINGLE HISTONE DEACETYLASES (HDACS)
    Jungel, A.
    Hemmatazad, H.
    Maurer, B.
    Rodrigues, H. Maciejewska
    Pileckyte, M.
    Gay, R. E.
    Michel, B. A.
    Gay, S.
    Distler, O.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S72 - S72
  • [49] Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
    Ruzic, Dusan
    Djokovic, Nemanja
    Srdic-Rajic, Tatjana
    Echeverria, Cesar
    Nikolic, Katarina
    Santibanez, Juan F.
    PHARMACEUTICS, 2022, 14 (01)
  • [50] Targeting histone deacetylases for the treatment of cancer and inflammatory diseases
    Huang, Lili
    JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) : 611 - 616
12345